# UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study

Study · id `cardio:ct-nct07163624` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07163624](<https://clinicaltrials.gov/study/NCT07163624>), retrieved 18 November 2026. No person wrote or checked this page.

Also called: NCT07163624

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 211 participants.

## Technical summary

Registry record NCT07163624. Randomized; double masking; primary purpose treatment. Start 2025-03-22 (actual); primary completion 2025-11-21 (actual). Results not posted.

## Key facts

- Design: Interventional study; randomized; double masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 211 participants (enrolled count; ClinicalTrials.gov record NCT07163624, source copy `cardio:ctgov-nct07163624-2026-11-05`, retrieved 2026-11-18)
- Started: 2025-03-22 (actual) (ClinicalTrials.gov record NCT07163624, source copy `cardio:ctgov-nct07163624-2026-11-05`, retrieved 2026-11-18)
- Primary completion: 2025-11-21 (actual) (ClinicalTrials.gov record NCT07163624, source copy `cardio:ctgov-nct07163624-2026-11-05`, retrieved 2026-11-18)
- Completion: 2025-12-30 (actual) (ClinicalTrials.gov record NCT07163624, source copy `cardio:ctgov-nct07163624-2026-11-05`, retrieved 2026-11-18)
- Countries: China (ClinicalTrials.gov record NCT07163624, source copy `cardio:ctgov-nct07163624-2026-11-05`, retrieved 2026-11-18)
- Care setting: Not reported
- Registry status: "COMPLETED" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07163624-2026-11-05`, retrieved 2026-11-18)

## The registry's words

- Brief title: UBT251 Injection Phase II (Type 2 Diabetes Mellitus) Study
- Acronym: T2DM
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Intervention (Drug): UBT251 Injection 2.0 mg and UBT251 Injection Placebo
- Intervention (Drug): UBT251 Injection 4.0 mg (ID 0.5 mg) and UBT251 Injection Placebo
- Intervention (Drug): UBT251 Injection 4.0 mg (ID 1.0 mg) and UBT251 Injection Placebo
- Intervention (Drug): UBT251 Injection 6.0 mg and UBT251 Injection Placebo
- Intervention (Drug): Semaglutide Injection (Ozempic®)
- Lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd.
- Lead sponsor class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry intervention name matches this record once doses, forms and salt words are removed: Semaglutide (`cardio:semaglutide`)
- Registry intervention is a member of this class by a sourced record link: GLP-1 receptor agonists (drug class) (`cardio:glp1-receptor-agonists`)
- Registry lists this organization as the lead sponsor: The United Bio-Technology (Hengqin) Co., Ltd. (`cardio:org-the-united-bio-technology-hengqin-co-ltd`)

## Provenance

Content hash: 97c13ef69e148ce0a30bb037f55d6471f9d495d30fcc5e3f27ecb2b23468a606
Last substantive edit: 2026-11-18
Evidence last checked: Not recorded
